[go: up one dir, main page]

CO6420374A2 - Efectos anti-perdida de hueso y pérdida de anti-adherimiento de una composición oral - Google Patents

Efectos anti-perdida de hueso y pérdida de anti-adherimiento de una composición oral

Info

Publication number
CO6420374A2
CO6420374A2 CO11114807A CO11114807A CO6420374A2 CO 6420374 A2 CO6420374 A2 CO 6420374A2 CO 11114807 A CO11114807 A CO 11114807A CO 11114807 A CO11114807 A CO 11114807A CO 6420374 A2 CO6420374 A2 CO 6420374A2
Authority
CO
Colombia
Prior art keywords
loss
test compound
adhering
bone
effects
Prior art date
Application number
CO11114807A
Other languages
English (en)
Inventor
Virginia Barnes
Harsh M Trivedi
Nicola Partridge
Emi Shimizu
Tao Xu
Wei Wang
Original Assignee
Colgate Palmolive Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42328354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6420374(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Colgate Palmolive Co filed Critical Colgate Palmolive Co
Publication of CO6420374A2 publication Critical patent/CO6420374A2/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • G01N33/56955Bacteria involved in periodontal diseases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486Metalloendopeptidases (3.4.24)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención divulga un método para determinar la utilidad de varios compuestos en el tratamiento de enfermedades y condiciones de la cavidad oral. En una realización, el método comprende contactar una célula con un compuesto de prueba, y determinar si el compuesto de prueba regula decrecientemente al menos una metaloproteinasa de la matriz seleccionada a partir de MMP-9 y MMP-13, en donde la regulación decreciente de la menos una de las metaloproteinasas de matriz, es una indicación que el compuesto de prueba es útil para tratar la periodontitis. La invención resulta particularmente útil en el campo de composiciones orales y de identificación de compuestos útiles en las mismas, a través de sus propiedades químicas.
CO11114807A 2009-04-01 2011-09-06 Efectos anti-perdida de hueso y pérdida de anti-adherimiento de una composición oral CO6420374A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16568509P 2009-04-01 2009-04-01

Publications (1)

Publication Number Publication Date
CO6420374A2 true CO6420374A2 (es) 2012-04-16

Family

ID=42328354

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11114807A CO6420374A2 (es) 2009-04-01 2011-09-06 Efectos anti-perdida de hueso y pérdida de anti-adherimiento de una composición oral

Country Status (20)

Country Link
US (1) US8637266B2 (es)
EP (1) EP2414838B1 (es)
JP (1) JP5330596B2 (es)
CN (1) CN102365550B (es)
AR (1) AR076177A1 (es)
AU (1) AU2010232590B2 (es)
BR (1) BRPI1013185A2 (es)
CA (1) CA2757317C (es)
CO (1) CO6420374A2 (es)
DK (1) DK2414838T3 (es)
ES (1) ES2432864T3 (es)
HK (1) HK1167272A1 (es)
MX (1) MX2011008438A (es)
MY (1) MY158406A (es)
PL (1) PL2414838T3 (es)
RU (1) RU2524629C2 (es)
SG (1) SG173487A1 (es)
TW (1) TWI405565B (es)
WO (1) WO2010115031A1 (es)
ZA (1) ZA201106054B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101745067B1 (ko) * 2014-12-31 2017-06-12 서울대학교산학협력단 치주질환 예측 시스템 및 이를 이용한 치주질환 예측 방법
KR102098624B1 (ko) * 2019-09-20 2020-04-08 서울대학교산학협력단 타액 mmp-9 및 il-8를 이용한 치주염 예측 시스템 및 이를 이용한 치주염 예측 방법

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3538230A (en) 1966-12-05 1970-11-03 Lever Brothers Ltd Oral compositions containing silica xerogels as cleaning and polishing agents
US4358437A (en) 1978-11-29 1982-11-09 Beecham Group Limited Compositions
US4894220A (en) 1987-01-30 1990-01-16 Colgate-Palmolive Company Antibacterial antiplaque oral composition
US5288480A (en) 1987-01-30 1994-02-22 Colgate-Palmolive Co. Antiplaque antibacterial oral composition
US5032386A (en) 1988-12-29 1991-07-16 Colgate-Palmolive Company Antiplaque antibacterial oral composition
GB9117140D0 (en) 1991-08-08 1991-09-25 Unilever Plc Treatment of periodontitis
DE4226043A1 (de) 1992-08-06 1994-02-10 Haarmann & Reimer Gmbh Mittel mit physiologischem Kühleffekt und für diese Mittel geeignete wirksame Verbindungen
US5756361A (en) * 1992-12-17 1998-05-26 Metra Biosystems, Inc. Screening method for periodontal disease
US5840302A (en) 1993-11-10 1998-11-24 Bristol-Myers Squibb Company Treatment of bacterially-induced inflammatory diseases
FI98961C (fi) * 1994-08-26 1997-09-10 Medix Biochemica Ab Oy Menetelmät ja määritysvälineet parodontaalisairauden aktiivisuuden ja/tai peri-implantiitin ja/tai niiden kohonneen riskin diagnosoimiseksi
US5578295A (en) 1995-04-28 1996-11-26 The Procter & Gamble Company Oral care compositions comprising certain substituted diphenyl ethers
WO1997047282A1 (de) 1996-06-12 1997-12-18 Henkel Kommanditgesellschaft Auf Aktien Kosmetische und/oder pharmazeutische zubereitungen
US5998487A (en) * 1998-04-08 1999-12-07 Colgate-Palmolive Company Anti-inflammatory and antibacterial benzyl phenol agents and their use in oral compositions
JP3763075B2 (ja) * 1998-04-24 2006-04-05 サンスター株式会社 歯周病の予防又は治療用の食品組成物、口腔用組成物及び医薬組成物
FR2794457B1 (fr) 1999-06-01 2001-08-10 Oreal Derives carbonates de retinol, procede de preparation et utilisations
US6165447A (en) * 1999-06-15 2000-12-26 Colgate-Palmolive Company Synergistic antibacterial combination
EP2295968B1 (en) 1999-12-03 2012-09-19 Baxter International Inc. Pyrogenicity test for use with automated immunoassay systems
GB0001704D0 (en) 2000-01-25 2000-03-15 Glaxo Group Ltd Protein
US7329489B2 (en) 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
EP1285092A4 (en) 2000-04-14 2003-07-16 Metabolon Inc METHOD FOR DISCOVERY OF MEDICINES, DISEASE TREATMENT AND DIAGNOSIS USE THE METABOLOMICS
US6500409B1 (en) 2000-05-10 2002-12-31 Colgate Palmolive Company Synergistic antiplaque/antigingivitis oral composition
DE10059584A1 (de) 2000-11-30 2002-06-06 Beiersdorf Ag Kosmetische oder dermatologische getränkte Tücher
DOP2002000332A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
MXPA05001786A (es) * 2002-08-13 2005-04-25 Warner Lambert Co Derivados de azaisoquinolina como inhibidores de la metaloproteinasa de matriz.
US7005225B2 (en) 2002-11-12 2006-02-28 Samsung Electronics Company Organosol including amphipathic copolymeric binder having crystalline material, and use of the organosol to make dry tones for electrographic applications
PL378108A1 (pl) 2003-02-14 2006-03-06 Combinatorx, Incorporated Leczenie łączone do terapii zapalnych zaburzeń immunologicznych
GB2401865A (en) 2003-05-22 2004-11-24 Givaudan Sa Antibacterial and antifungal glycerol monocarbonates
EP1697389A4 (en) 2003-10-24 2008-12-24 Eisai R&D Man Co Ltd COMPOUNDS AND METHODS FOR TREATING ILLNESS AND SUFFERING TOLL-LIKE RECEPTOR 2 RELATED DISORDERS
JP2007519894A (ja) 2003-12-03 2007-07-19 ホワイトヘッド インスティテュート フォー バイオメディカル リサーチ 標的としてのカドヘリンの使用
FI20040572A0 (fi) * 2004-04-23 2004-04-23 Ctt Cancer Targeting Tech Oy Matriisi-metalloproteinaasin aktiviteetin inhibiittorit
JP4662043B2 (ja) * 2004-09-09 2011-03-30 国立大学法人東京農工大学 歯周病発症の評価システム
CN101111288A (zh) * 2004-12-02 2008-01-23 高露洁-棕榄公司 含酚类化合物和抗氧化剂维生素和维生素衍生物的口腔护理组合物
US20060141421A1 (en) 2004-12-28 2006-06-29 Kimberly-Clark Worldwide, Inc. System and method for detecting substances related to oral health
WO2006074450A2 (en) 2005-01-07 2006-07-13 President And Fellows Of Harvard College Methods and compositions for detecting and modulating periodontal disorders and periodontal diseases
JP5024506B2 (ja) * 2005-03-25 2012-09-12 ライオン株式会社 歯周組織破壊の抑制・改善剤及び口腔用組成物
CA2849559A1 (en) 2006-01-10 2007-07-19 Colgate-Palmolive Company Methods of modulating cell surface receptors to prevent or reduce inflammation
US20080161394A1 (en) 2006-11-23 2008-07-03 Jean-Yves Fouron Cosmetic composition comprising at least one volatile carbonic acid ester
WO2008093072A2 (en) 2007-01-29 2008-08-07 Paul Webb Topical composition against contact dermatitis due to water
WO2009048841A1 (en) 2007-10-09 2009-04-16 Humco Holding Group, Inc. Antifungal treatment of nails
TWI481870B (zh) * 2009-04-01 2015-04-21 Colgate Palmolive Co 用於軟組織疾病診斷及作為用於口腔保健干預的標靶之蛋白質生物標記

Also Published As

Publication number Publication date
AU2010232590A1 (en) 2011-08-18
AU2010232590B2 (en) 2013-03-07
ES2432864T3 (es) 2013-12-05
CN102365550B (zh) 2014-08-13
WO2010115031A1 (en) 2010-10-07
TWI405565B (zh) 2013-08-21
JP5330596B2 (ja) 2013-10-30
EP2414838A1 (en) 2012-02-08
PL2414838T3 (pl) 2014-01-31
AR076177A1 (es) 2011-05-26
MY158406A (en) 2016-10-14
DK2414838T3 (da) 2013-11-04
HK1167272A1 (en) 2012-11-23
EP2414838B1 (en) 2013-08-28
US20120107843A1 (en) 2012-05-03
CA2757317A1 (en) 2010-10-07
CA2757317C (en) 2014-03-11
TW201039812A (en) 2010-11-16
MX2011008438A (es) 2011-09-06
JP2012524884A (ja) 2012-10-18
RU2011144028A (ru) 2013-05-10
CN102365550A (zh) 2012-02-29
US8637266B2 (en) 2014-01-28
RU2524629C2 (ru) 2014-07-27
SG173487A1 (en) 2011-09-29
BRPI1013185A2 (pt) 2016-04-12
ZA201106054B (en) 2014-01-29

Similar Documents

Publication Publication Date Title
CL2008002917A1 (es) Anticuerpos especificos para 5-ennolpiruvilshikimato-3-fosfato sintetasa (epsps) doble mutante; hibridoma productor; método para generar dichos anticuerpos; eodo de detección de dicha enzima epsps doble mutante en una composición; kit para detectar la presencia de dicha epsps doble mutante en la composición.
BRPI0713357A2 (pt) Inibidores de proteína tirosina fosfatase humana e método de utilização.
AR085702A1 (es) Metodos para predecir el rendimiento en plantas y aplicaciones de uso de los mismos
BRPI0713349A2 (pt) Inibidores de proteína tirosina fosfatase humana e métodos de utilização
BR112013002699A2 (pt) composições inibidoras de incrustação etiquetadas e métodos para inibir incrustação
CO6210786A2 (es) Implemento de cuidado oral que alberga un agente de cuidado oral
MX338535B (es) Inhibidores de ibat para el tratamiento de enfermeades hepaticas.
BR112015004881A2 (pt) método para diagnosticar o estado da doença periodontal e kit para diagnosticar o estado da doença periodontal
UA118649C2 (uk) ДВОЛАНЦЮГОВИЙ ЗАСІБ ДЛЯ PHKі ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ТРАНСТИРЕТИНУ (TTR)
BRPI1003281A2 (pt) Composição e método para maquilar um substrato queratínico
CO6351823A2 (es) Método de identificación de factores de riesgo de la enfermedad
FR2925826B1 (fr) Composition inhibitrice d'urease et de nitrification
PE20091858A1 (es) Composiciones herbicidas que comprenden piroxasulfona
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
BRPI1002771A2 (pt) Composição e método para maquilar um substrato queratínico
ATE461699T1 (de) Verbesserte biologische wirkungen von zusammensetzungen, die rosmarinsäure enthalten
CR8341A (es) Una composicion y metodo de tratamiento para condiciones urogenitales
BR112012027704A2 (pt) método para fabricação e utilização de aço inoxidável ferrítico-austenítico com alta formabilidade
BRPI0712889A8 (pt) composto, processo para a preparação de um composto, composto intermediário, e, composição farmacêutica.
BRPI1010804A2 (pt) "método para fabricação de carbodiimidas"
ATE375810T1 (de) Cyanoamid-verbindungen als nützliche malonyl-coa decarboxylase-hemmer
ECSP066557A (es) Métodos y composiciones para inhibición de selectina
CO6420374A2 (es) Efectos anti-perdida de hueso y pérdida de anti-adherimiento de una composición oral
ATE400272T1 (de) Piperidin-verbindungen als malonyl-coa decarboxylase-hemmer
PA8599301A1 (es) Compuestos de benzopirano para uso en el tratamiento y la prevencion de afecciones relacionadas con la inflamacion

Legal Events

Date Code Title Description
FC Application refused